| 24044 |
Amivantamab |
Rybrevant® |
Amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI) |
Rapid Review Complete |
12th February 2026 |
 |
| 26002 |
Budesonide targeted-release formulation (TRF) |
Kinpeygo® |
Budesonide TRF (Kinpeygo®) is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥ 1.0g/day (or urine protein-to-creatinine ratio ≥ 0.8 g/g). |
Rapid Review Complete |
9th February 2026 |
|
| 22013 |
Caplacizumab |
Cablivi® |
Treatment of adults and adolescents aged 12 years and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. |
Rapid Review complete |
12th February 2026 |
|
| 25067 |
Donanemab |
Kisunla® |
Donanemab (Kisunla™) is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early symptomatic Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers with confirmed amyloid pathology. |
Awaiting full HTA submission from Applicant |
16th February 2026 |
|
| 24035 |
Dupilumab |
Dupixent® |
Dupilumab is indicated in adults as an add-on maintenance treatment for uncontrolled COPD characterised by raised blood eosinophils on a combination of an ICS, a LABA, and a LAMA, or on a combination of a LABA and a LAMA, if an ICS is not appropriate. |
Awaiting full HTA submission from Applicant |
12th February 2026 |
|
| 23026 |
Efgartigimod alfa |
Vyvgart® |
Efgartigimod alfa is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis who are anti-acetylcholine receptor antibody positive. |
Awaiting full HTA submission from Applicant |
12th February 2026 |
|
| 23008 |
House dust mite allergen extract |
Actair® |
Dermatophagoides pteronyssinus and Dermatophagoides farinae in equal parts (Actair®) is indicated for the treatment of moderate-to-severe house dust mite (HDM)–induced allergic rhinitis (AR) or rhinoconjunctivitis diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test [SPT] and/or specific immunoglobulin E [IgE]) in adolescents (aged 12-17 years) and adults. |
Rapid Review Complete |
12th February 2026 |
|
| 23024 |
Isatuximab |
Sarclisa® |
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone, is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
Rapid Review Complete |
12th February 2026 |
|
| 22048 |
Melatonin |
Slenyto® |
For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient. |
Rapid Review Complete |
12th February 2026 |
|
| - |
Obeticholic acid |
Ocaliva® |
For the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. |
NCPE Assessment Process Complete |
6th February 2026 |
|
| 26005 |
Odevixibat |
Kayfanda® |
Odevixibat (Kayfanda®) is indicated for the treatment of cholestatic pruritus in Alagille Syndrome (ALGS) in patients aged six months or older. |
Rapid Review Complete |
26th February 2026 |
|
| 23014 |
Olipudase alfa |
Xenpozyme® |
As an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B. |
Rapid Review Complete |
12th February 2026 |
|
| 24030 |
Pegylated Liposomal irinotecan |
Onivyde® |
Liposomal irinotecan in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. |
Rapid Review Complete |
12th February 2026 |
|
| 23058 |
Pembrolizumab |
Keytruda® |
Pembrolizumab as monotherapy for the treatment of mismatch repair deficient or microsatellite instability-high tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. |
Rapid Review Complete |
12th February 2026 |
|
| 23078 |
Pembrolizumab |
Keytruda® |
Pembrolizumab (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy*. |
NCPE Assessment Process Complete |
19th February 2026 |
|
| 23079 |
Sacituzumab govitecan |
Trodelvy® |
Sacituzumab govitecan is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. |
Rapid Review Complete |
12th February 2026 |
|
| 26003 |
Seladelpar |
Lyvdelzi® |
Seladelpar (Lyvdelzi®) is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. |
Pre-submission consultation scheduled |
6th February 2026 |
|
| 25024 |
Semaglutide |
Wegovy® |
Semaglutide (Wegovy®) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (BMI) of • ≥30kg/m2 (obesity), or • ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. |
Full HTA submission received from Applicant |
23rd February 2026 |
|
| 24003 |
Tirzepatide |
Mounjaro® |
Tirzepatide (Mounjaro®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. |
Full HTA submission received from Applicant |
9th February 2026 |
|
| 24028 |
Trastuzumab deruxtecan |
Enhertu® |
As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. |
Rapid Review Complete |
12th February 2026 |
|
| 25049 |
Trastuzumab deruxtecan |
Enhertu® |
Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. |
Awaiting full HTA submission from Applicant |
25th February 2026 |
|
